Abstracts tagged "Biomarkers"

Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Ranjan Gupta¹, Sonam Rajput², Jayanth Kumar² and Dipendra K Mitra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
Abstract Number: 0741 • ACR Convergence 2024
Serum Markers of Disease Activity in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: A significant unmet need in Polymyalgia Rheumatica (PMR) is the lack of a disease specific serum biomarker for diagnosis, and monitoring of disease activity.…
Abstract Number: 0883 • ACR Convergence 2024
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Jorge Monserrat¹, Cristina Bohorquez², Ana Maria Gómez³, Elena Rabadán Rubio⁴, Raquel Sánchez³, Atusa Movasat⁵, Lucia Ruiz⁴, Fernando Albarran Hernandez⁶, Miguel Ángel Ortega¹, Ana Perez⁶ and Melchor Alvarez-Mon⁷, ¹Universidad de Alcalá. IRYCIS, Alcalá de Henares, Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ³Universidad de Alcalá, Alcalá de Henares, Madrid, Spain, ⁴Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁶Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁷Universidad de Alcalá. HUPA. IRYCIS, Madrid, Spain

Background/Purpose: Rheumatoid arthritis (RA) is a highly inflammatory severe chronic autoimmune disorder with an inadequate activation of the immune cells. These cells are responsible for…
Abstract Number: 1122 • ACR Convergence 2024
Clinical Realities in Patients with Adult Onset Still’s Disease: Real-World Diagnosis and Management
Chloe Heiting¹, Karen Gambina² and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medical College, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Adult Onset Still’s Disease (AOSD) is a rare systemic inflammatory disorder characterized by inflammatory polyarthritis, daily fever, and a transient salmon-pink maculopapular rash. Diagnosis…
Abstract Number: 1388 • ACR Convergence 2024
CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Ting Wang¹, Ryan Stultz¹, Natalia Giltiay², Christian Lood¹ and Bobby Kwanghoon Han¹, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, USA, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). We conducted this study to identify novel predictive and…
Abstract Number: 1654 • ACR Convergence 2024
CRTAC1 in Osteoarthritis: Implications for Disease Severity and miRNA Regulation
Aneta Prokopcová¹, Jiri Baloun², Adéla Navrátilová³, Klára Mocová², Lucia Ondrejčáková⁴, Jana Juhaszova², Tereza Kropáčková¹, Hana Storkanova⁵, Michal Tomcik⁵, Jindriska Gatterova², Olga Sleglova², Olga Ruzickova², Eva Kriegova⁶, Jiri Gallo⁷, Rastislav Ballay⁸, Petr Fulin⁹, Jiří Vencovský¹ and Ladislav Šenolt¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³1st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia, Olomouc, Czech Republic, ⁷Department of Orthopaedics, University Hospital Olomouc, Olomouc, Czech Republic, ⁸1st Faculty of Medicine, Charles University, Prague, Czechia, Prague, Czech Republic, ⁹1st Department of Orthopaedics, First Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czechia, Prague, Czech Republic
Background/Purpose: Cartilage acidic protein1 (CRTAC1) is a potential biomarker linked to osteoarthritis (OA) and cartilage degeneration. This study aimed to compare CRTAC1 levels in the…
Abstract Number: 1905 • ACR Convergence 2024
Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Bryant England¹, Austin Wheeler¹, Brent Luedders¹, Michael Duryee¹, Halie Frideres², Katherine Wysham³, grant Cannon⁴, Gary Kunkel⁵, Dana Ascherman⁶, Paul Monach⁷, Gail Kerr⁸, Andreas Reimold⁹, Joshua Baker¹⁰, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷VA Boston Healthcare System, Boston, MA, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Several peripheral biomarkers for RA-associated interstitial lung disease (RA-ILD) have been evaluated to enhance early RA-ILD identification. The MUC5B rs35705950 promoter variant, matrix metalloproteinase-7…
Abstract Number: 2234 • ACR Convergence 2024
Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
Sung Hae Chang¹, Yong-Beom Park², Gregory McDermott³, Misti Paudel⁴, Keigo Hayashi³, You-Jung Ha⁵, Jeong Seok Lee⁶, Min Uk Kim⁷, Chan Ho Park⁸, Sang Wan Chung⁹, Ji-Won Kim¹⁰, Jang Woo Ha¹¹, Sung Won Lee¹², Eun Ha Kang⁵, Yeon-Ah Lee¹³, Jung-Yoon Choe¹⁴, Eun Young Lee¹⁵ and Jeffrey Sparks¹⁶, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, ¹Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ²Yonsei University College of Medicine, Seoul, Republic of Korea, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Seoul National University Bundang Hospital, Seongnam, South Korea, ⁶Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, ⁹Kyung Hee University Hospital, Seoul, Republic of Korea, ¹⁰Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, ¹¹Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, ¹²Soonchunhyang University Cheonan Hospital, Seoul, South Korea, ¹³Kyung Hee University Hospital, Seoul, South Korea, ¹⁴Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ¹⁵3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ¹⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (ILD) is a heterogeneous disease with a chronic course and potential for flares. Serum biomarkers are needed to identify those…
Abstract Number: 2425 • ACR Convergence 2024
Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
Marianna Rowlands¹, Thomas Dörner², Diego Saldana Miranda³, Justin McMullen³, Aida Santos da Costa³, Ulrike Sommer³, Rainer Hillenbrand³, Andre Nogueira da Costa³, Claire Bonal³, Isabelle Isnardi³, Edward Khokhlovich¹ and Stephen J Oliver³, ¹Biomedical Research, Novartis, Cambridge, MA, ²Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ³Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736), a B cell activating factor receptor (BAFFR) targeting mAb, depletes B cells via both antibody dependent cellular cytotoxicity and blockade of BAFF:BAFFR…
Abstract Number: 2637 • ACR Convergence 2024
Chaperone-mediated Autophagy in Synovitis Distinguishes Psoriatic Arthritis from Rheumatoid Arthritis
Vincenzo Venerito¹, Gerardo Cazzato², Fabio Cacciapaglia³, Eleonora Ceglie⁴, Sergio Del Vescovo⁴, Teresa Caferri⁴, Giuseppe Lopalco⁴, Francesco Girolamo⁵ and Florenzo Iannone¹, ¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²Pathology Unit - University of Bari "Aldo Moro", IT, Bari, Italy, ³Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁴Rheumatology Unit - University of Bari "Aldo Moro", IT, Bari, Italy, ⁵Human Anatomy Department - University of Bari "Aldo Moro", IT, Bari, Italy
Background/Purpose: Recent studies have suggested that autophagy may play different roles in the pathogenesis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Lysosome-associated membrane protein type 2A…
Abstract Number: 0043 • ACR Convergence 2024
Inflammatory and Angiogenic Serum Profile of Refractory Rheumatoid Arthritis
Manon Lesturgie-Talarek¹, Virginie Gonzalez², ALICE COMBIER³, Marion THOMAS⁴, Margaux Boisson⁵, Sandrine Carves³, Sarah Wanono³, Lucie Poiroux³, Anne Cauvet¹, Sophie Hecquet⁶, Yannick Allanore⁷ and Jérôme Avouac⁸, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, Ile-de-France, France, ³Hôpital Cochin - Université Paris Cité, Paris, France, ⁴APHP, Paris, France, ⁵Hôpital Cochin - Université Paris Cité, Paris, ⁶Cochin Hospital, Paris, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Despite the emergence of new therapies, a considerable proportion of individuals with rheumatoid arthritis (RA) still endure symptoms, giving rise to the concept of…
Abstract Number: 0334 • ACR Convergence 2024
Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity
shiri keret¹, Tanya Chandra², Lisa Kaly³, Raisa Silva⁴, Eugenia Gkiaouraki⁵, Nantakarn Pongtarakulpanit⁶, shreya Sriram⁵, Rajesh Gopalarathinam⁷, Siamak Mogahadam⁶, Chester Oddis⁶ and Rohit Aggarwal⁸, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ⁴Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Creatine kinase (CK) is an important biomarker for the diagnosis and monitoring of Idiopathic Inflammatory Myopathies (IIM). However, in some cases, CK levels might…
Abstract Number: 0494 • ACR Convergence 2024
Usefulness of the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio and the Systemic Immune Inflammatory Index in Assessing Disease Activity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Ventura Mejia², guillermo velarde² and Graciela Alarcon³, ¹Hncase, Arequipa, Peru, ²UNIVERSIDAD NACIONAL DE SAN AGUSTIN, arequipa, Peru, ³The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) causes systemic inflammation that leads to specific changes in the patients’ blood cells; this offers the opportunity to measure inflammatory activity…
Abstract Number: 0640 • ACR Convergence 2024
7000-Plex Proteomic Screen of Urine for Flare Monitoring and Treatment Response Biomarkers in Active Lupus Nephritis
kamala Vanarsa¹, Yewei Ma², Mohammad Daouk², Vinaika Maruvada², Ramesh Saxena³ and Chandra Mohan⁴, ¹University of Houston, houstton, ²University of Houston, Houston, ³UT Southwestern Medical Center, Dallas, ⁴University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with lupus. Since the kidney biopsy is invasive, better, more predictive…
Abstract Number: 0763 • ACR Convergence 2024
Transcriptional Analysis of Both Normal and Abnormal TABs in Biopsy-proven GCA Reveals a Shared Gene Expression Profile Compared to Clinically Diverse Controls
Ingrid Lindquist¹, Dongseok Choi², Suzanne Fei³, Kiana Vakil-Gilani⁴, Daniela Ghetie¹, David Wilson⁵, Diva Salomao⁶, Hillary Stiefel⁷, Daniel Albert⁷, James Rosenbaum⁸ and Marcia Friedman¹, ¹OHSU, Division of Arthritis and Rheumatic Diseases, Portland, OR, ²OHSU, School of Public Halth, Portland, OR, ³OHSU, Oregon National Primate Research Center, Portland, OR, ⁴OHSU, Division of Arthritis and Rheumatic Diseases, Porltand, OR, ⁵OHSU, Casey Eye Institute, Porrtland, OR, ⁶Mayo Clinic, Division of Anatomic Pathology, Rochester, MN, ⁷OHSU, Casey Eye Institute, Portland, OR, ⁸Corvus Pharmaceuticals and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over 50 years old and is a clinical diagnosis bolstered by pathologic findings on temporal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.